A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer

We conducted an open-label single-arm phase II study by combining irinotecan (FOLFIRI) and bevacizumab (BV) plus erlotinib (ER) in 2nd-line chemotherapy for patients with metastatic colorectal cancer (mCRC). Eligible mCRC patients received 1st-line standard chemotherapy but still had progressive dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zhifei, Li, Jianxiong, Ye, Rui, Wu, Xuan, Gao, Lingling, Niu, Baolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627801/
https://www.ncbi.nlm.nih.gov/pubmed/28746175
http://dx.doi.org/10.1097/MD.0000000000007182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627801/
https://www.ncbi.nlm.nih.gov/pubmed/28746175
http://dx.doi.org/10.1097/MD.0000000000007182

Ejemplares similares